This research blend combines two peptides that labs use to study growth hormone release signaling in controlled research models. CJC-1295 (No DAC), often described in research contexts as a short-acting, modified form of a growth hormone releasing hormone fragment, is used to observe one “side” of the GH release pathway, while ipamorelin is used to study the other “side” by interacting with the growth hormone secretagogue (ghrelin) receptor system. In combination research conditions, labs typically watch timing and pattern changes in GH-related signaling under defined experimental parameters rather than treating it like a guaranteed “result.”
All products are intended for in vitro or laboratory research use only. This compound is not intended for therapeutic or diagnostic purposes and has not been approved by the FDA for human or veterinary use.
** This product is supplied as a lyophilized powder blend and requires reconstitution with an appropriate solution (commonly BAC water) prior to research use.